Specifically, autologous or allogeneic NK cells are expanded and activated under the stimulus of feeder cells, such as gene-modified K562 cells and cytokines (IL-2/IL-15) in vitro, and then infused back into patients to eliminate tumor cells in vivo through direct cytotoxicity and cytokine secretion [13,14]. The gene discussed is IL15; the disease is neoplasm.